EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.
Recruiting · NCT05570149 · Observational (researchers observe without assigning treatment) · Lead sponsor: IRCCS San Raffaele Roma
View the official record on ClinicalTrials.gov →Interventions studied
Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution
What this trial is about
The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Age between 18 and 75 years;
- Males and females;
- Willingness to sign the informed consent;
- High frequency episodic migraine, at least 8 days per month of disabling migraine in the past 3 months;
- Chronic migraine, according to the ICHD-III criteria;
- KEY
Exclusion criteria
- Other headaches different than migraine;
- Known intolerance to eptinezumab or eccipients;
- Current treatment with other mAbs;
- Vascular disease or Raynaud.
Where it is running
1 location listed.
- IRCCS San Raffaele Roma - Roma, RM, Italy